VDR and prostate carcinoma: In prostate cancer, treatment with the PRL inhibitor S179D PRL upregulated the expression of SF1b thus leading to upregulation of p21, a cell cycle inhibiting protein, and the vitamin D receptor known to promote differentiation [32].